Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection.
作者信息
Coelho Ana R, Oliveira Paulo J
机构信息
CNC-Center for Neuroscience and Cell Biology, UC-Biotech, University of Coimbra, Cantanhede, Portugal.
出版信息
Eur J Clin Invest. 2020 Oct;50(10):e13366. doi: 10.1111/eci.13366. Epub 2020 Aug 16.
Abstract
摘要
相似文献
1
Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection.二氢乳清酸脱氢酶抑制剂在新冠病毒感染中的作用
Eur J Clin Invest. 2020 Oct;50(10):e13366. doi: 10.1111/eci.13366. Epub 2020 Aug 16.
2
Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.二氢乳清酸脱氢酶（DHODH）抑制剂“来氟米特”和“特立氟胺”在新冠病毒感染中的疗效和安全性：一项叙述性综述。
Eur J Pharmacol. 2021 Sep 5;906:174233. doi: 10.1016/j.ejphar.2021.174233. Epub 2021 Jun 7.
3
Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase.人二氢乳清酸脱氢酶抑制剂对新型冠状病毒肺炎的潜在治疗作用
Protein Cell. 2020 Oct;11(10):699-702. doi: 10.1007/s13238-020-00769-9.
4
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.新型、强效二氢乳清酸脱氢酶（DHODH）抑制剂是广谱抗 RNA 病毒药物，可针对包括新型冠状病毒 SARS-CoV-2 在内的多种 RNA 病毒。
Protein Cell. 2020 Oct;11(10):723-739. doi: 10.1007/s13238-020-00768-w. Epub 2020 Aug 4.
5
Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.开发一种生物标志物，用于监测二氢乳清酸脱氢酶抑制剂治疗后的靶标结合情况。
Biochem Pharmacol. 2022 Oct;204:115237. doi: 10.1016/j.bcp.2022.115237. Epub 2022 Aug 31.
6
Inhibition of canine distemper virus replication by blocking pyrimidine nucleotide synthesis with A77 1726, the active metabolite of the anti-inflammatory drug leflunomide.用抗炎药物来氟米特的活性代谢产物 A77 1726 阻断嘧啶核苷酸合成抑制犬瘟热病毒复制。
J Gen Virol. 2021 Mar;102(3). doi: 10.1099/jgv.0.001534. Epub 2021 Jan 8.
7
Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse.尽管因多发性硬化症复发接受了特立氟胺和高剂量甲泼尼龙治疗，但仍出现轻度新冠症状。
J Neurol. 2020 Oct;267(10):2803-2805. doi: 10.1007/s00415-020-09921-1. Epub 2020 May 28.
8
COVID-19 in teriflunomide-treated patients with multiple sclerosis.新冠肺炎在多发性硬化症接受特立氟胺治疗的患者中。
J Neurol. 2020 Oct;267(10):2790-2796. doi: 10.1007/s00415-020-09944-8. Epub 2020 Jun 3.
9
Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models.研究二氢乳清酸脱氢酶抑制剂介导的肝体外模型中线粒体功能障碍。
Toxicol In Vitro. 2021 Apr;72:105096. doi: 10.1016/j.tiv.2021.105096. Epub 2021 Jan 16.
10
Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?多发性硬化症中干扰素-β的三十年：我们能否将这些信息用于治疗新型冠状病毒2感染？
Front Immunol. 2020 Jun 18;11:1459. doi: 10.3389/fimmu.2020.01459. eCollection 2020.
引用本文的文献
1
Effects of metabolic cancer therapy on tumor microenvironment.代谢性癌症疗法对肿瘤微环境的影响。
Front Oncol. 2022 Dec 13;12:1046630. doi: 10.3389/fonc.2022.1046630. eCollection 2022.
2
The Novel DHODH Inhibitor MEDS433 Prevents Influenza Virus Replication by Blocking Pyrimidine Biosynthesis.新型 DHODH 抑制剂 MEDS433 通过阻断嘧啶生物合成来预防流感病毒复制。
Viruses. 2022 Oct 17;14(10):2281. doi: 10.3390/v14102281.
3
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-]pyridine Scaffold: SAR of the Aryloxyaryl Moiety.基于 2-羟基吡唑并[1,5-a]嘧啶骨架的高效人二氢乳清酸脱氢酶抑制剂靶向治疗急性髓性白血病：芳氧基芳基部分的 SAR。
J Med Chem. 2022 Oct 13;65(19):12701-12724. doi: 10.1021/acs.jmedchem.2c00496. Epub 2022 Sep 26.
4
Development of accelerated high-throughput antiviral screening systems for emerging orthomyxoviruses.新兴正粘病毒的高通量抗病毒筛选系统的快速开发。
Antiviral Res. 2022 Apr;200:105291. doi: 10.1016/j.antiviral.2022.105291. Epub 2022 Mar 13.
5
Human/SARS-CoV-2 genome-scale metabolic modeling to discover potential antiviral targets for COVID-19.利用人/SARS-CoV-2全基因组规模代谢模型发现COVID-19的潜在抗病毒靶点。
J Taiwan Inst Chem Eng. 2022 Apr;133:104273. doi: 10.1016/j.jtice.2022.104273. Epub 2022 Feb 15.
6
Atovaquone and Berberine Chloride Reduce SARS-CoV-2 Replication In Vitro.阿托伐醌和盐酸小檗碱可降低 SARS-CoV-2 的体外复制。
Viruses. 2021 Dec 4;13(12):2437. doi: 10.3390/v13122437.
7
A Bioluminescent 3CL Activity Assay to Monitor SARS-CoV-2 Replication and Identify Inhibitors.一种用于监测 SARS-CoV-2 复制和鉴定抑制剂的生物发光 3CL 活性测定法。
Viruses. 2021 Sep 12;13(9):1814. doi: 10.3390/v13091814.
8
The New Generation DHODH Inhibitor MEDS433 Hinders the In Vitro Replication of SARS-CoV-2 and Other Human Coronaviruses.新一代二氢乳清酸脱氢酶（DHODH）抑制剂MEDS433可抑制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其他人类冠状病毒的体外复制。
Microorganisms. 2021 Aug 14;9(8):1731. doi: 10.3390/microorganisms9081731.
9
Metabolism and Innate Immunity Meet at the Mitochondria.新陈代谢与固有免疫在 mitochondria 相遇。 （注：这里 mitochondria 一般译为“线粒体”，但按照要求未进行修改）
Front Cell Dev Biol. 2021 Jul 27;9:720490. doi: 10.3389/fcell.2021.720490. eCollection 2021.
10
SARS-CoV-2 Antiviral Therapy.SARS-CoV-2 抗病毒治疗。
Clin Microbiol Rev. 2021 Dec 15;34(4):e0010921. doi: 10.1128/CMR.00109-21. Epub 2021 Jul 28.
本文引用的文献
1
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.新型、强效二氢乳清酸脱氢酶（DHODH）抑制剂是广谱抗 RNA 病毒药物，可针对包括新型冠状病毒 SARS-CoV-2 在内的多种 RNA 病毒。
Protein Cell. 2020 Oct;11(10):723-739. doi: 10.1007/s13238-020-00768-w. Epub 2020 Aug 4.
2
A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.《COVID-19 指南：由新型冠状病毒 SARS-CoV-2 引起的全球大流行》。
FEBS J. 2020 Sep;287(17):3633-3650. doi: 10.1111/febs.15375. Epub 2020 Jun 16.
3
The hallmarks of COVID-19 disease.新型冠状病毒疾病的特征。
PLoS Pathog. 2020 May 22;16(5):e1008536. doi: 10.1371/journal.ppat.1008536. eCollection 2020 May.
4
Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis.维地福卢米单抗钙，一种用于治疗复发缓解型多发性硬化症的新一代二氢乳清酸脱氢酶抑制剂。
Mult Scler Relat Disord. 2020 Aug;43:102129. doi: 10.1016/j.msard.2020.102129. Epub 2020 May 6.
5
BHRF1, a BCL2 viral homolog, disturbs mitochondrial dynamics and stimulates mitophagy to dampen type I IFN induction.BHRF1，一种 BCL2 病毒同源物，扰乱线粒体动力学并刺激线粒体自噬，以抑制 I 型 IFN 的诱导。
Autophagy. 2021 Jun;17(6):1296-1315. doi: 10.1080/15548627.2020.1758416. Epub 2020 May 13.
6
Diabetes or endocrinopathy admitted in the COVID-19 ward.因糖尿病或内分泌疾病入住新冠病房。
Eur J Clin Invest. 2020 Jul;50(7):e13262. doi: 10.1111/eci.13262. Epub 2020 May 24.
7
Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects.健康男性受试者单次及多次递增口服剂量维达氟啶钙（IMU-838）后的安全性、耐受性和药代动力学
Eur J Drug Metab Pharmacokinet. 2020 Oct;45(5):557-573. doi: 10.1007/s13318-020-00623-7.
8
The trinity of COVID-19: immunity, inflammation and intervention.COVID-19 的三位一体：免疫、炎症和干预。
Nat Rev Immunol. 2020 Jun;20(6):363-374. doi: 10.1038/s41577-020-0311-8. Epub 2020 Apr 28.
9
Linking mitochondria to the immune response.将线粒体与免疫反应联系起来。
Elife. 2020 Apr 15;9:e56214. doi: 10.7554/eLife.56214.
10
Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease.利用先天免疫来清除严重急性呼吸综合征冠状病毒2（SARS-CoV-2）并改善冠状病毒病（COVID-19）病情。
Physiol Genomics. 2020 May 1;52(5):217-221. doi: 10.1152/physiolgenomics.00033.2020. Epub 2020 Apr 10.
Zotero 插件